CEFALY Technology Introduces CEFALY@Work: A Workplace Wellness Initiative for Employees With Migraine

DARIEN, Conn., May 27, 2025 /PRNewswire/ -- Medical device maker CEFALY Technology today announced the launch of CEFALY@Work, a new offering that gives companies the tools to better support employees with migraine.

CEFALY@Work helps companies reduce migraine-related absenteeism, presenteeism, and healthcare costs by offering CEFALY's neuromodulation treatment device and support tools as part of their corporate wellness or benefits program. 

CEFALY@Work is currently in the pilot phase. CEFALY Technology is forging new partnerships with U.S.-based companies to make this innovative, drug-free treatment available to their employees.

The impact of migraine in the workplace

Migraine is a neurological disorder that can cause severe headaches, nausea, light and sound sensitivity, fatigue, and other disabling symptoms.

Migraine affects 1 in 5 women and 1 in 7 employees overall. While the severity and frequency of symptoms vary, migraine causes 4+ lost workdays per migraine patient per year, on average, and ranks in the top five causes of long-term disability.

Research has found that people report being only 46% effective when working during a migraine attack. However, many feel they have no choice but to struggle through the pain.

Migraine has a long history of being stigmatized and misunderstood — not only because it's a largely invisible illness, but because it predominantly affects women. Because of this stigma, more than half of workers who are absent because of migraine headache do not disclose the real reason to employers. 

"Migraine silently erodes productivity, retention, and morale," said Jen Trainor-McDermott, CEO of CEFALY Technology. "It's time we treat it like the workplace issue it truly is — and that's why we've launched CEFALY@Work."

Solutions provided by CEFALY@Work 

CEFALY Technology's FDA-cleared wearable device is clinically proven to prevent and relieve migraine symptoms without the harmful side effects of migraine medication. Used by more than 200,000 patients and trusted in U.S. VA hospitals, CEFALY is based on more than 20 years of research.

"Migraine patients prefer CEFALY because it's safe and effective, without the brain fog and other adverse side effects of prescription medication, " said Trainor-McDermott. "CEFALY benefits employers because it helps employees with migraine reach their fullest potential — and lowers the costs of care, compared to prescription medications or long-term disability claims."

CEFALY@Work is a three-tiered program:

• The Starter tier offers employees a discount on CEFALY devices.
• The Premium tier enables employees to get a CEFALY device and companion electrodes free of charge from their employer.
• The Enterprise tier adds device usage data insights, onboarding webinars and support tools.

All tiers also receive custom-branded education and wellness materials, as well as free employee access to personalized support from a CEFALY Coach. The CEFALY device is supported by a mobile app that reinforces usage, tracking, and stress management tools.

CEFALY Technology is currently seeking organizations to participate in the pilot of CEFALY@Work. Those interested in a potential partnership can learn more here. 

About CEFALY Technology:
CEFALY Technology is the maker of CEFALY, an FDA-cleared, over-the-counter wearable medical device clinically proven to help reduce migraine frequency and relieve migraine pain. CEFALY Technology is a Belgium-based company with its U.S. offices based in Darien, Conn., specializing in electronics for medical applications. CEFALY Technology's mission is to provide innovative, ever-evolving technology that enables people with migraine to take control of their treatment and live happier, healthier lives.

Learn more about CEFALY by visiting CEFALY.com and following us on Facebook, X, LinkedIn, Instagram and TikTok.

Media Contact:
CEFALY
Jen Trainor-McDermott
CEO
[email protected]

SOURCE CEFALY Technology